Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with evidence of activity in myeloid malignancies and cutaneous T cell lymphoma. Thirteen HL patients were treated with escalating doses of this novel agent in a phase IA/II multicentre study. A computed tomography partial response was achieved in 5/13(38%), and a metabolic response by (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scanning in 7/12 (58%) evaluable patients. This report describes the preliminary evidence of anti-tumour activity seen in the early phase of this study, which recently closed to accrual.
Dickinson
Michael
M
Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Ritchie
David
D
DeAngelo
Daniel J
DJ
Spencer
Andrew
A
Ottmann
Oliver G
OG
Fischer
Thomas
T
Bhalla
Kapil N
KN
Liu
Angela
A
Parker
Katie
K
Scott
Jeffrey W
JW
Bishton
Mark
M
Prince
H Miles
HM
D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D019788:Fluorodeoxyglucose F18; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D007211:Indoles; D008297:Male; D008875:Middle Aged; D000077767:Panobinostat; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D055815:Young Adult
D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007211:Indoles; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000077767:Panobinostat